-
公开(公告)号:US10167254B2
公开(公告)日:2019-01-01
申请号:US15584818
申请日:2017-05-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: James Aaron Balog , Emily Charlotte Cherney , Weiwei Guo , Audris Huang , Jay A. Markwalder , Steven P. Seitz , Weifang Shan , David K. Williams , Natesan Murugesan , Susheel Jethanand Nara , Saumya Roy , Soodamani Thangavel , Ramesh Kumar Sistla , Srinivas Cheruku , Srinivasan Thangathirupathy , Yadagiri Kanyaboina , Nagalakshmi Pulicharla
IPC: A61K31/17 , C07C275/40 , A61K31/196 , A61K31/277 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/428 , A61K31/437 , A61K31/445 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K31/538 , A61K39/395 , C07C229/42 , C07C255/58 , C07D205/04 , C07D211/14 , C07D239/47 , C07D265/36 , C07D277/64 , C07D295/155 , C07D309/04 , C07D335/02 , C07D401/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D309/14 , C07D407/12 , C07D487/08 , C07D265/30 , C07D207/08 , C07D211/08 , C07D307/22 , C07C255/57 , C07C235/38 , C07C235/56 , C07C233/81 , C07C275/42 , C07D207/12 , C07D239/34 , C07D317/46 , C07D413/14 , C07D471/08 , C07C275/30 , A61K45/06
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
-
公开(公告)号:US20180312491A1
公开(公告)日:2018-11-01
申请号:US15767386
申请日:2016-10-13
Applicant: Bristol-Myers Squibb Company
Inventor: Imadul Islam , Srinivasan Thangathirupathy , Jayakumar Sankara Warrier , Srinivas Cheruku , Poornima Shetty , Grandhi Venkat Ram Krishna Mohan Gupta , John E. Macor
IPC: C07D403/14 , C07D401/14 , C07D487/08 , A61P25/24 , A61P25/28 , A61P25/02 , A61P25/16
CPC classification number: C07D403/14 , A61P25/02 , A61P25/16 , A61P25/24 , A61P25/28 , C07D401/12 , C07D401/14 , C07D471/08 , C07D487/08
Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
-
公开(公告)号:US20130085138A1
公开(公告)日:2013-04-04
申请号:US13627130
申请日:2012-09-26
Applicant: Bristol-Myers Squibb Company
Inventor: Dalton King , Richard E. Olson , John E. Macor , Imadul Islam , Srinivasan Thangathirupathy , Jayakumar Sankara Warrier
IPC: A61K31/4709 , A61K31/4245 , C07D413/14 , A61K31/501 , A61K31/498 , A61P29/00 , C07D487/04 , A61K31/519 , A61K31/506 , A61P25/24 , A61P25/28 , A61P25/16 , C07D413/12 , A61K31/538
CPC classification number: C07D413/12 , C07D271/113 , C07D401/12 , C07D403/08 , C07D413/06 , C07D413/08 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04
Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
Abstract translation: 本公开内容通常涉及式I化合物,包括其盐,以及使用该化合物的组合物和方法。 这些化合物是NR2B受体的配体,拮抗剂,可用于治疗中枢神经系统的各种疾病。
-
公开(公告)号:US10959986B2
公开(公告)日:2021-03-30
申请号:US16555634
申请日:2019-08-29
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: James Aaron Balog , Steven P. Seitz , Susheel Jethanand Nara , Saumya Roy , Srinivasan Thangathirupathy , Soodamani Thangavel , Ramesh Kumar Sistla
IPC: A61K31/415 , A61K31/5377 , C07D231/12 , C07D401/12 , C07D403/12 , C07D261/08 , C07D277/22 , C07D285/08 , C07D211/60 , C07D317/50 , C07D307/36 , C07D333/54 , C07D231/56 , C07D221/22 , C07D471/04 , C07D487/04 , A61K31/17 , A61K31/4439 , A61K31/506 , A61K31/42 , A61K31/426 , A61K31/433 , A61K31/357 , A61K31/341 , A61K31/381 , C07C275/42
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.
-
公开(公告)号:US20200071304A1
公开(公告)日:2020-03-05
申请号:US16502684
申请日:2019-07-03
Applicant: Bristol-Myers Squibb Company
Inventor: Imadul Islam , Srinivasan Thangathirupathy , Jayakumar Sankara Warrier , Srinivas Cheruku , Poornima Shetty , Grandhi Venkat Ram Krishna Mohan Gupta , John E. Macor
IPC: C07D403/14 , C07D401/12 , C07D471/08 , A61P25/28 , A61P25/02 , A61P25/24 , A61P25/16 , C07D401/14 , C07D487/08
Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
-
公开(公告)号:US20200069695A1
公开(公告)日:2020-03-05
申请号:US16555431
申请日:2019-08-29
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: James Aaron Balog , Steven P. Seitz , Susheel Jethanand Nara , Saumya Roy , Srinivasan Thangathirupathy , Soodamani Thangavel , Srinivas Cheruku
IPC: A61K31/5377 , C07C275/42 , A61K31/17 , C07D277/64 , A61K31/428 , C07C211/54 , A61K31/136 , C07D239/47 , A61K31/505 , A61K31/275 , C07D241/18 , A61K31/4965 , C07D239/42 , A61K31/5375 , C07D295/03 , C07D413/12
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.
-
公开(公告)号:US10344020B2
公开(公告)日:2019-07-09
申请号:US15767386
申请日:2016-10-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Imadul Islam , Srinivasan Thangathirupathy , Jayakumar Sankara Warrier , Srinivas Cheruku , Poornima Shetty , Grandhi Venkat Ram Krishna Mohan Gupta , John E. Macor
IPC: C07D403/14 , C07D401/12 , C07D471/08 , A61P25/28 , A61P25/02 , A61P25/24 , A61P25/16 , C07D401/14 , C07D487/08
Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
-
公开(公告)号:US20190117638A1
公开(公告)日:2019-04-25
申请号:US16225850
申请日:2018-12-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Dalton King , Lorin A. Thompson, III , Jianliang Shi , Srinivasan Thangathirupathy , Jayakumar Sankara Warrier , Imadul Islam , John E. Macor
IPC: A61K31/454 , C07D403/04 , C07D401/04
Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
-
公开(公告)号:US20180000807A1
公开(公告)日:2018-01-04
申请号:US15706172
申请日:2017-09-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Dalton King , Lorin A. Thompson, III , Jianliang Shi , Srinivasan Thangathirupathy , Jayakumar Sankara Warrier , Imadul Islam , John E. Macor
IPC: A61K31/454 , C07D403/04 , C07D401/04
CPC classification number: A61K31/454 , C07D401/04 , C07D403/04
Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
-
公开(公告)号:US09221796B2
公开(公告)日:2015-12-29
申请号:US14589205
申请日:2015-01-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Dalton King , Lorin A. Thompson, III , Jianliang Shi , Srinivasan Thangathirupathy , Jayakumar Sankara Warrier , Imadul Islam , John E. Macor
IPC: C07D403/04 , C07D401/04
CPC classification number: A61K31/454 , C07D401/04 , C07D403/04
Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
Abstract translation: 本公开内容通常涉及式I化合物,包括其盐,以及使用该化合物的组合物和方法。 这些化合物是NR2B受体的配体,可用于治疗中枢神经系统的各种疾病。
-
-
-
-
-
-
-
-
-